Latigo Biotherapeutics
- Market cap
- 1.03B
- P/E (TTM)i
- -9.26
- P/Bi
- -3.73
- EPSi
- -1.82
- Div yieldi
- 0.00%
- 52W posi
- 2%
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
- The number of reporting institutions increased by 10 in the most recent period (2026/Q3).
- Total institutional ownership rose 65.5 percentage points.
Institutional ownership
- Held by institutions
- 65.54% +65.54pp
- Institutions
- 10 +10
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
DivergingInstitutions added shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Top holders as of 2026-08-10
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
20 filings tracked · 6 buys · 0 sells
| Name | Role | Stake |
|---|---|---|
| Westlake Village BioPartners | -- | 19.91% |
| Foresite Capital Management, LLC | -- | 13.85% |
| 5AM Venture Management, LLC | -- | 11.05% |
| Timothy Walbert | Independent Chairperson | 0.50% |
| Sara Bonstein | Independent Director | 0.16% |
| James Tananbaum | Independent Director | -- |
| Sanofi | -- | -- |
| Andrew Schwab | -- | -- |
| Todd Smith | Independent Director | -- |
| Nima Farzan | Chief Executive Officer | -- |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-08-09 | Sanofi | -- | Derivative Exercise and Retained | +672,778 | -- |
| 2026-08-09 | 5AM Venture Management, LLC | -- | Derivative Exercise and Retained | +7,325,962 | -- |
| 2026-08-09 | Foresite Capital Management, LLC | -- | Open Market Acquisition | +140,000 | $18.00 |
| 2026-08-09 | Foresite Capital Management, LLC | -- | Derivative Exercise and Retained | +9,041,328 | -- |
| 2026-08-09 | Westlake Village BioPartners | -- | Derivative Exercise and Retained | +12,695,305 | -- |
| 2026-08-05 | James Tananbaum | Independent Director | Initial Statement of Beneficial | 0 | -- |
| 2026-08-05 | Sanofi | -- | Initial Statement of Beneficial | 0 | -- |
| 2026-08-05 | Andrew Schwab | -- | Initial Statement of Beneficial | 0 | -- |
| 2026-08-05 | Timothy Walbert | Independent Chairperson | Initial Statement of Beneficial | 0 | -- |
| 2026-08-05 | Todd Smith | Independent Director | Other Derivative Acquisition | +105,542 | $18.00 |
| 2026-08-05 | Nima Farzan | Chief Executive Officer | Initial Statement of Beneficial | 0 | -- |
| 2026-08-05 | Sara Bonstein | Independent Director | Initial Statement of Beneficial | 0 | -- |
| 2026-08-05 | Westlake Village BioPartners | -- | Initial Statement of Beneficial | 0 | -- |
| 2026-08-05 | Neha Krishnamohan | Chief Business Officer & CFO | Initial Statement of Beneficial | 0 | -- |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-07 19:54:59 · For reference only, not investment advice and not tailored to your situation.